Clinical trials: sponsored by Hoffmann-La Roche
Breast Cancer
A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in Germany
This non-interventional study will collect data from routine diagnostics on HER2 testing of breast cancer in Germany.
- Trial name
- NCT02666261
- Where
- 64 sites in Germany
- Volunteers
- 15,000 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
This multi-center, observational study will evaluate the efficacy and safety of dual and triple therapies based on Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis C.
- Trial name
- NCT01604291
- Where
- 21 sites in Israel
- Volunteers
- 991 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
This multi-center, randomized study compared the efficacy and safety of MabThera (rituximab) in combination with either fludarabine and cyclophosphamide or with chlorambucil in participants with previously untreated B-cell…
- Trial name
- NCT01283386
- Testing
- Chlorambucil, Cyclophosphamide, Fludarabine
- Where
- 8 sites in Russia
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Geographic Atrophy
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96…
- Trial name
- NCT02745119
- Testing
- Lampalizumab
- Where
- 208 sites in United States, Australia and 17 more
- Volunteers
- 994 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
This multicenter, prospective, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in first-line therapy in elderly patients with metastatic colorectal cancer.
- Trial name
- NCT01555762
- Where
- 166 sites in France
- Volunteers
- 402 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility Study
This prospective pilot study will assess the feasibility of remote participant monitoring using digital technology in participants with MS and healthy controls.
- Trial name
- NCT02952911
- Testing
- Smartphone and Smartwatch
- Where
- 2 sites in United States, Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
This randomized, open-label study was designed to evaluate and compare the safety and efficacy of atezolizumab with gemcitabine + cisplatin or carboplatin in PD-L1 selected participants with chemotherapy-naive, Stage IV squamous…
- Trial name
- NCT02409355
- Testing
- Atezolizumab, Carboplatin, Cisplatin
- Where
- 82 sites in United States, Czechia and 12 more
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Melanoma
A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])
This is a multicentre, ambispective (both retrospective and prospective), and non-interventional study conducted in France in adult participants with BRAF V600 mutation-positive unresectable or metastatic melanoma treated with…
- Trial name
- MELANIS (NCT03139513)
- Testing
- Cobimetinib, Vemurafenib
- Where
- 33 sites in France
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
Colorectal Neoplasms
A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
This open-label, prospective, single-arm, multicenter study will evaluate the relationship of the markers of inflammation and progression-free survival (PFS) in participants with previously untreated metastatic colorectal cancer.
- Trial name
- ASCENT (NCT01588990)
- Testing
- Oxaliplatin, Capecitabine, Bevacizumab
- Where
- 17 sites in Australia
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
This is a Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of bevacizumab administered in combination with paclitaxel in patients with previously untreated, locally…
- Trial name
- NCT01663727
- Testing
- Bevacizumab [Avastin], Paclitaxel
- Where
- 178 sites in United States, Argentina and 14 more
- Volunteers
- 481 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)
This single arm study will assess the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide, followed by rituximab maintenance therapy, as first line treatment of participants with CLL.
- Trial name
- NCT00545714
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 33 sites in Spain
- Volunteers
- 86 people
- Sponsor
- Hoffmann-La Roche
Hepatitis D, Chronic
A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
This randomized, single blind study will compare the antiviral effect of Pegasys (pegylated interferon alfa-2a) plus placebo versus Pegasys plus tenofovir in patients with chronic hepatitis D.
- Trial name
- NCT01088659
- Testing
- peginterferon alfa-2a [Pegasys], tenofovir
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer, Peritoneal Neoplasms
BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer
This non-interventional study will evaluate the routine use and the safety and efficacy of Avastin (bevacizumab) as first-line treatment in patients with advanced ovarian cancer (epithelial ovarian cancer, fallopian tube…
- Trial name
- NCT01788995
- Where
- Austria
- Volunteers
- 63 people
- Sponsor
- Hoffmann-La Roche
Stroke
A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke
This Phase IIa, randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety, efficacy and pharmacodynamics of basmisanil in adult participants with severe motor impairment following an ischemic…
- Trial name
- NCT02928393
- Testing
- Basmisanil
- Where
- 13 sites in France, Spain
- Volunteers
- 5 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease, Healthy Volunteer
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants
This study is designed to obtain basic information on three PET imaging tracers developed to detect tau pathology in the brain. In this study, healthy control participants and participants with AD will be studied.
- Trial name
- NCT02187627
- Testing
- [11C]RO6924963, [11C]RO6931643, [18F]RO6958948
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Lymphoma, Non Hodgkin
MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma
This open-label, single-arm, phase IIIb study will evaluate the safety of switching from intravenous (IV) to subcutaneous (SC) administration of rituximab during first-line treatment for participants with CD20+ non-Hodgkin's…
- Trial name
- NCT01987505
- Testing
- Rituximab
- Where
- 39 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic
A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia
This randomized, parallel-group, multi-center study will compare the pharmacokinetics and safety of subcutaneous administration of MabThera (rituximab) versus intravenous MabThera in combination with chemotherapy in previously…
- Trial name
- NCT01292603
- Testing
- Cyclophosphamide, Fludarabine, rituximab [MabThera]
- Where
- 84 sites in Argentina, Australia and 17 more
- Volunteers
- 240 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment
This nationwide, multicenter, single arm, prospective, non-interventional study will evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use in a representative cohort of…
- Trial name
- CONIFER (NCT03112213)
- Testing
- Tocilizumab, NSAIDs
- Where
- 27 sites in Germany
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Healthy Participants
Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants
The purpose of this study is to assess the relative bioavailability of the high concentration liquid formulation (HCLF) of gantenerumab produced with the G4 process in comparison to the same HCLF of gantenerumab produced with the…
- Trial name
- NCT03236844
- Testing
- Gantenerumab
- Where
- 3 sites in United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
This open-label study will evaluate the efficacy and safety of tocilizumab as monotherapy or in combination with methotrexate or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) in participants with active…
- Trial name
- ACT-MOVE (NCT02046603)
- Testing
- Tocilizumab, DMARDs, Oral Corticosteroids
- Where
- 38 sites in United Kingdom
- Volunteers
- 162 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.